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TGF-b1 is a multifunctional cytokine that mediates
diverse biological processes. However, the mecha-
nisms by which the intracellular signals of TGF-b1
are terminated are not well understood. Here,
we demonstrate that DRAK2 serves as a TGF-b1-
inducible antagonist of TGF-b signaling. TGF-b1
stimulation rapidly induces DRAK2 expression and
enhances endogenous interaction of the type I
TGF-b receptor with DRAK2, thereby blocking
R-Smads recruitment. Depletion of DRAK2 expres-
sion markedly augmented the intensity and the
extent of TGF-b1 responses. Furthermore, a high
level of DRAK2 expression was observed in basal-
like and HER2-enriched breast tumors and cell lines,
and depletion of DRAK2 expression suppressed the
tumorigenic ability of breast cancer cells. Thus, these
studies define a function for DRAK2 as an intrinsic
intracellular antagonist participating in the negative
feedback loop to control TGF-b1 responses, and
aberrant expression of DRAK2 increases tumori-
genic potential, in part, through the inhibition of
TGF-b1 tumor suppressor activity.
INTRODUCTION
Transforming growth factor-b1 (TGF-b1) is a multifunctional
cytokine that regulates cell proliferation, differentiation, migra-
tion, and apoptosis (Massague´ et al., 2000; Massague´, 2008).
TGF-b1 signals through type I and type II serine/threonine kinase
receptors (TbRI and TbRII) and their intracellular mediators
known as Smad proteins. TGF-b1 ligand initially binds to TbRII
and recruits TbRI, thereby forming heteromeric complexes1286 Cell Reports 2, 1286–1299, November 29, 2012 ª2012 The Autbetween TbRI and TbRII. In TbR complexes, TbRII phosphory-
lates TbRI, leading to the activation of a TbRI kinase domain,
which, in turn, phosphorylates the receptor-associated Smads
(R-Smads; Smad2 and Smad3) at their C-terminal serine resi-
dues. Phosphorylated R-Smads form heteromeric complexes
with common mediator Smad (Co-Smad; Smad4) and then
translocate to the nucleus where they act as a transcriptional
regulator for TGF-b1 target genes (Shi and Massague´, 2003;
Feng and Derynck, 2005; Massague´ et al., 2005). Beside
R-Smads and Co-Smad, the inhibitory Smads (I-Smads;
Smad6 and Smad7) play key roles in TGF-b signaling, pro-
viding negative regulation through interaction of TbRI (Hayashi
et al., 1997).
Dysregulation of negative feedback of TGF-b signaling influ-
ences tumor growth. Among the negative regulators, all of which
are direct target genes of TGF-b signaling, I-Smads, transmem-
brane prostate androgen-induced RNA (TMEPAI), Ski-related
novel protein N (SnoN), and Smad ubiquitination regulatory
factors (Smurfs) play key roles in the negative regulation of
TGF-b signaling (Itoh and ten Dijke, 2007; Watanabe et al.,
2010). Overexpression of Smad7 has been recently shown to
promote inhibition of TGF-b signaling in human pancreatic,
colorectal, skin, and breast cancers (Yan et al., 2009). Moreover,
it has been reported that TMEPAI inhibits TGF-b signaling by
interfering TbRI-mediated R-Smads phosphorylation, thus
antagonizing the tumor-suppressive effects of TGF-b1 in breast
cancer (Watanabe et al., 2010). Therefore, disruption of TGF-b
signaling caused by elevated levels of its negative regulators
can lead to the development of TGF-b1-associated human
cancers.
DRAK2 (DAP kinase-related apoptosis-inducing protein
kinase 2), also referred to as STK17B, is known as a negative re-
gulator for T cell activation (Sanjo et al., 1998; McGargill et al.,
2004). It is a serine/threonine kinase belonging to the death-
associated protein kinase (DAPK) family and is identified as a
proapoptotic protein kinase (Bialik and Kimchi, 2006). However,hors
among the DAPK family, the role of DRAK2 in the regulation of
apoptosis is still controversial. In one transgenic mouse model,
DRAK2 induces increased T cell apoptosis and aggravated
b cell apoptosis when triggered by apoptosis-inducing stimuli,
whereas drak2-deficient mice did not show any defects in
apoptosis and retroviral expression of DRAK2 did not lead
to the increase of apoptosis in NIH 3T3 or T cells (Kuwahara
et al., 2006; Mao et al., 2006, 2009; McGargill et al., 2004).
Although the physiological functions of DRAK2 have been exten-
sively examined in the thymus, many aspects regarding this
kinase, including the significance of its expression, intracellular
localization, and binding partners and catalytic substrates
remain to be elucidated in other tissues.
Here, we identify a role for DRAK2 as an antagonist of TGF-b
signaling, which may act in the negative feedback loop to regu-
late the intensity or the duration of the TGF-b signal. DRAK2
specifically interacted with TbRI, thereby blocking the phosphor-
ylation of Smad2/3, which is the core process in the canonical
TGF-b signaling. DRAK2 was highly expressed in basal-like
and HER2-enriched human breast tumors as well as in the
basal-like breast cancer cell lines. Furthermore, loss of DRAK2
expression inhibited tumor growth in a xenograft model, sug-
gesting that increased expression of DRAK2 may promote
tumorigenesis by constraining the TGF-b1 tumor suppressor
activity.
RESULTS
DRAK2 Specifically Interacts with TbRI
We performed mass spectrometry-based proteomic screen
of TGF-b receptor-associated proteins in HEK293 cells stably
expressing HA-tagged TGF-b receptors to identify novel binding
partners of TGF-b receptors (Figure 1A). Sequence analysis
showed that one of these peaks identified by mass spectrom-
etry contained DRAK2. To confirm the interaction of TbRI with
human DRAK2, 293T cells were cotransfected with Myc-tagged
DRAK2 and HA-tagged TbRI and then treated with or without
TGF-b1. DRAK2 specifically interacted with TbRI (Figure 1B).
Although subcellular localization of DAPK family members is
dependent on the cell type, only DRAK2 is known to localize
to both the cytosol and the nucleus (McGargill et al., 2004).
Next, we examined the subcellular distribution of DRAK2 and
TbRI in HeLa cells. Comparison of the subcellular distribution
of DRAK2 and TbRI by confocal microscopy revealed extensive
overlap (Figure 1C). We also confirmed the interaction or coloc-
alization between DRAK2 and TbRI by in situ proximity ligation
assay (PLA), a specific and highly sensitive method for detecting
this protein-protein interaction. The signals from the proximally
localized proteins are amplified as red dots in the in situ PLA.
Confocal imaging showed that DRAK2 interacted with TbRI on
the cell membrane as well as in the cytosol (Figure 1D). To
further elaborate the physiological significance of the interaction
between DRAK2 and TbRI, we examined the endogenous inter-
action of DRAK2 with TbRI. As expected, endogenous DRAK2
interacted with endogenous TbRI in anti-TbRI immunocom-
plexes (Figure 1E). As ectopic expression of TbRI could form
a complex with the endogenous TbRII even in the absence of
the ligand, we examined whether the interaction betweenCell ReDRAK2 and TbRI requires TbRII using SNU638 gastric cancer
cell line, which is known to be TbRII deficient (Chang et al.,
1997). When TbRI was immunoprecipitated by anti-TbRI anti-
body, endogenous DRAK2 directly bound to TbRI without the
help of TbRII (Figure 1F). Interestingly, the interaction between
DRAK2 and TbRI was increased by TGF-b1 treatment (Fig-
ure 1B). Based on the fact that TbRI can be activated by TbRII
only through the formation of heteromeric complexes between
TbRI and TbRII, we investigated whether kinase function of
TbRI is required for its interaction with DRAK2. We used a series
of TbRI mutants (constitutively active mutant; CA, kinase dead
mutant; KD, and Smad-binding region mutant; mL45) to
examine DRAK2-binding capability. When coexpressed with
a series of TbRI mutants, DRAK2 bound to wild-type as well
as to each type of the TbRI mutant examined (Figure 1G). We
also observed that the interaction between DRAK2 and TbRI
was increased depending on the degree of kinase activity of
TbRI. Interestingly, mL45 mutant of TbRI, which has lost the
ability to interact with Smads due to the mutation in the L45
loop of the kinase domain (Yu et al., 2002), was capable of
binding to DRAK2, suggesting that DRAK2 might bind to the
regions other than Smads-binding regions of TbRI. To determine
the minimal binding domain of TbRI, we designed a glutathione
S-transferase (GST) pull-down assay with GST-fused TbRI cyto-
plasmic domain deletion mutants. DRAK2 was only able to bind
to a TbRI kinase domain, but not to a GS domain alone (Fig-
ure 1H). To further define the domain in TbRI responsible for
DRAK2 binding, we generated a series of deletion mutants of
a TbRI kinase domain fused to GST and performed GST precip-
itation assays. DRAK2 was associated with TbRI kinase domain
deletion mutants containing amino acids 216–220, whereas a
TbRI kinase domain deletion mutant lacking residues 216–220
failed to interact with DRAK2 (Figure 1I), suggesting that resi-
dues 216–220 in TbRI are critical for interaction with DRAK2.
Next, we generated single or double amino-acid-substitution
mutants of TbRI cytoplasmic domain (216–220) fused to GST
(Figure 1J and S1). Single amino-acid-substitution mutants in
residues 216–224 did not affect binding of TbRI (149–450) to
DRAK2 (Figure S1). However, substitution of the Val-Trp at
positions 219–220 with Ala-Ala reduced interactions of TbRI
(149–450) to DRAK2 (Figure 1J).
DRAK2 Suppresses TGF-b Signaling
To investigate whether the interaction of DRAK2 with TbRI
plays a role in TGF-b signaling, we tested the effect of
DRAK2 expression on TGF-b signaling using TGF-b1-respon-
sive reporters (SBE-Luc and 3TP-Luc) in various TGF-b1-
responsive cell lines, including Hep3B, HepG2 (hepatocellular
carcinoma), and HeLa (cervical cancer) cells. Overexpres-
sion of DRAK2 significantly decreased the TGF-b1-induced
transcriptional activity of either SBE-Luc or 3TP-Luc (Figures
2A, S2A, and S2B). To further investigate the functional signif-
icance of DRAK2 in TGF-b signaling, we performed gain-
of-function experiments by generating lentivirus-transduced
stable cell lines expressing DRAK2 protein. Overexpression
of DRAK2 significantly inhibited the TGF-b1-induced Smad2
and Smad3 phosphorylation (Figures 2B, 2C, S2C, and S2D)
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Figure 1. DRAK2 Specifically Interacts with TbRI
(A) The protocol of a TbRI-binding-partner screen using purification methods.
(B) 293T cells were cotransfected with Myc-tagged DRAK2 and HA-tagged TbRI with or without TGF-b1 for 2 hr. Cell lysates were immunoprecipitated with
anti-HA antibody and analyzed by immunoblots using anti-HA and anti-Myc antibodies.
(C) Myc-tagged DRAK2 andHA-tagged TbRI were cotransfected in HeLa cells. After transfection, cells were fixed for immunofluorescence. Ectopic expression of
DRAK2 and TbRI was visualized using confocal microscopy (green and red, respectively).
(D) Interactions between Myc-tagged DRAK2 and HA-tagged TbRI expressed in HeLa cells were visualized by in situ proximity ligation assay (in situ PLA). In situ
PLA signals were visualized in red.
(E) Cell lysates from HeLa cells were immunoprecipitated with antinormal IgG or anti-TbRI antibodies and subjected to immunoblots with anti-DRAK2 antibody.
(F) SNU638 gastric cancer cells were subjected to whole-cell lysis followed by SDS-PAGE, and cell lysates were immunoprecipitated with antinormal IgG,
anti-TbRI, or anti-TbRII antibodies and then detected by immunoblots.
(G) 293T cells were cotransfected with Myc-tagged DRAK2 and HA-tagged TbRI wild-type (WT), kinase active (CA), kinase dead form (KD), or Smad binding
defective (mL45) and then immunocomplexes of DRAK2 and TbRI mutant constructs were captured using anti-Myc antibody.
(H) Immunoblot analysis of 293T cells cotransfected with plasmids encoding GST-fused TbRI containing its full cytoplasmic region (149–450) or the GS domain
(149–204), and Myc-tagged DRAK2. Cells were collected and lysates were mixed with glutathione agarose beads; bound proteins were identified by immunoblot
analysis with anti-Myc antibody.
(I) GST pull-down assay of Myc-tagged DRAK2 bound to GST-fused deletion mutants of TbRI.
(J) GST pull-down assay of Myc-tagged DRAK2 bound to GST-fused double amino-acid-substitution mutant TbRI.
See also Figure S1.to the nucleus in confocal microscopy and subcellular fraction-
ation (Figures 2D and 2E). To verify a function of DRAK2 as
a negative regulator of TGF-b signaling in vivo, we monitored
the expression of TGF-b1 target genes such as p15Ink4b,
p21Waf1/Cip1, PAI1, and IL11 by RT-PCR in HaCaT cells that
stably overexpress DRAK2. These results demonstrated that1288 Cell Reports 2, 1286–1299, November 29, 2012 ª2012 The AutDRAK2-overexpressing cells responded with diminished sensi-
tivity to TGF-b1 in terms of induction of TGF-b1 target genes
(Figure 2F).
Next, we investigated the significance of DRAK2-bindingmotif
in TbRI in TGF-b signaling. We generated the TbRI expression
construct lacking DRAK2-binding site. Then, HeLa cells werehors
cotransfected with HA-tagged TbRI WT or TbRI V219A/W220A
mutant and Myc-tagged DRAK2. DRAK2 inhibited TGF-b1-
induced Smad3 phosphorylation and transcriptional activity in
TbRI WT-transfected cells. However, DRAK2 failed to block
TGF-b1-induced Smad3 phosphorylation in the presence of
TbRI mutant lacking DRAK2-binding site. The inhibitory activity
of TGF-b1-induced reporter activity by DRAK2 was also mark-
edly reduced in the presence of TbRI mutant lacking DRAK2-
binding site (Figures 2G and 2H). This result indicates that
DRAK2 inhibits TGF-b signaling through interaction with resi-
dues 219–220 in TbRI. Interestingly, overexpression of TbRI
V219A/W220A mutant slightly enhanced TGF-b1-induced
reporter activity, suggesting that the inhibitory activity of
TGF-b signaling by endogenous DRAK2 may be relieved by
the expression of the TbRI mutant lacking DRAK2-binding
site. The TbRI region required for the interaction with DRAK2
appears to be conserved among other type I receptors of
TGF-b family (Figure S3A). To confirm whether DRAK2 interacts
with other type I receptors of TGF-b family, we performed the
immunoprecipitation assay. As expected, DRAK2 also inter-
acted with all type I receptors of TGF-b family (Figure S3B).
To examine the possibility whether DRAK2 inhibits activin or
bone morphogenetic protein (BMP) signaling, we investigated
the effect of DRAK2 expression on activin or BMP signaling
using activin- or BMP-response reporters (ARE- or BMP-Luc).
Overexpression of DRAK2 decreased the TGF-b1-induced
transcriptional activity of ARE-Luc and BMP2-induced tran-
scriptional activity of BMP-Luc (Figures S3C and S3D). There-
fore, it is likely that DRAK2 also inhibits signaling of activin
or BMP.
We next sought to elucidate the underlying mechanism
by which DRAK2 suppresses TGF-b/Smads signaling via its
association with TbRI. We first investigated whether DRAK2
blocks complex formation between TbRI and TbRII. Ectopic
expression of DRAK2 led to its binding with TbRI, but this
binding did not inhibit the interaction between TbRI and TbRII
(Figure S4A). We also tested whether DRAK2 suppresses the
phosphorylation of Smad2 and Smad3 through direct bind-
ing to either of them. However, DRAK2 did not interact
with either Smad2 or Smad3 (Figure S4B). Therefore, we ex-
amined whether DRAK2 interrupts Smad2/3 and TbRI com-
plex formation, which is critical in boosting cellular TGF-b1
responses. We found that ectopic expression of DRAK2 dimin-
ished TGF-b1-induced interaction of TbRI and Smad3. Further-
more, the level of Smad3 bound to active TbRI (HA-Alk5 ca)
was inversely related to the level of DRAK2 expression (Fig-
ure 2I). Taken together, these data suggest that interaction
between DRAK2 and TbRI results in an interruption of com-
plex formation between TbRI and Smad2/3, thereby contrib-
uting to the downregulation of Smad2/3-dependent cellular
responses.
Kinas Activity of DRAK2 Is Required for Inhibiting TGF-b
Signaling
As DRAK2 is a serine/threonine kinase and is able to autophos-
phorylate, we tested whether the kinase activity of DRAK2 is
required for the suppression of TGF-b signaling. We generated
a kinase-inactive mutant of DRAK2 by replacing lysine 62,Cell ReATP-binding site in the kinase domain, with alanine (Friedrich
et al., 2007). To confirm whether DRAK2 can autophosphorylate
in our hands, we examined DRAK2 kinase activity in 293T cells
transfected with Myc-tagged DRAK2 wild-type (WT) or Myc-
tagged DRAK2 K62A form. We incubated the lysates in a kinase
assay buffer containing 32P-ATP; DRAK2 WT autophosphory-
lated, whereas DRAK2 K62A failed to autophosphorylate
itself (Figure 3A). To determine whether autophosphorylation
of DRAK2 is required for the interaction of DRAK2 with TbRI,
we performed an immunoprecipitation assay in 293T cells co-
transfected with either Myc-tagged DRAK2 WT or Myc-tagged
DRAK2 K62A with HA-tagged TbRI. DRAK2 WT interacted
with TbRI, whereas kinase inactivation of DRAK2 decreased
its interaction with TbRI (Figure 3B). The ability of DRAK2 to
suppress TGF-b1-responsive reporter activity and Smad2/3
phosphorylation induced by TGF-b1 was also markedly attenu-
ated by a functional loss of DRAK2 as well (Figures 3C and 3D).
These results suggest that DRAK2 autophosphorylation may
alter the protein conformation to allow its interaction with
TbRI. DRAK2 homodimerization was then investigated as a
mechanism required for the autophosphorylation of DRAK2.
Myc-tagged DRAK2 WT was observed only in cells cotrans-
fected with GST-fused and Myc-tagged DRAK2 WT but not in
cells cotransfected with GST- or Myc-tagged DRAK2 K62A (Fig-
ure 3E). These results demonstrate that only wild-type DRAK2
monomers are capable of dimerization in vivo, suggesting that
homodimerization requires the autocatalytic activity of DRAK2.
Since DRAK2 is a serine/threonine kinase, to test whether
TbRI is a DRAK2 substrate, human GST-tagged recombinant
TbRI, TbRII, and DRAK2 proteins were generated for in vitro
kinase assay. We confirmed that recombinant DRAK2 protein
failed to trans-phosphorylate TbRI or TbRII proteins (data not
shown).
DRAK2 May Be Oncogenic in Human Breast Cancer
Based on the Oncomine (http://www.oncomine.org) and
BioGPS database (http://www.biogps.org), which revealed rela-
tively higher expression of DRAK2 in Hs578T breast cancer cell
lines than other cancer cells, we investigated the expression
level of DRAK2 in eight human breast cancer cell lines by quan-
titative RT-PCR. DRAK2 was highly expressed in the basal-like
breast cancer cell lines (Hs578T, MDA-MB-231, and MDA-MB-
435) compared to the luminal-like breast cancer cell lines (SK-
BR-3, ZR75B, BT-474, MCF-7, and T47D) (Figure 4A). We also
analyzed the expression of DRAK2 mRNA in different breast
tumor subtypes (normal-like, luminal A, luminal B, basal-like,
and HER2-enriched) using published microarray data sets
(Wang et al., 2005). Interestingly, a significantly embellished level
of DRAK2 expression was observed in basal-like and HER2-
enriched tumors compared to normal and luminal types (Figures
4B and 4C). We next tested the expression level of DRAK2 in
normal and primary human triple-negative breast tumor tissues.
RT-PCR analyses demonstrated increased expression of
DRAK2 mRNA in triple-negative breast tumor tissues compared
to normal tissues (Figure 4D). We also performed immunohisto-
chemistry using anti-DRAK2-specific antibody to investigate the
expression of DRAK2 in tumor and stromal compartments of
breast carcinomas. Expression of DRAK2 is mainly enriched inports 2, 1286–1299, November 29, 2012 ª2012 The Authors 1289
Figure 2. Overexpression of DRAK2 Suppresses the TGF-b Signaling Pathway
(A) Luciferase assay from lysates of HeLa cells cotransfected with TGF-b1-responsive reporters SBE- (left) or 3TP- (right), and Myc-tagged DRAK2, after
incubation for 16 hr with or without TGF-b1 treatment. Error bars indicate standard deviation of the mean (SDM) of three independent experiments.
(B and C) HeLa and HaCaT cells infected with GFP-expressing lentivirus (pCAG-GFP) or DRAK2-expressing lentivirus (pCAG-DRAK2) were treated with TGF-b1
for 1 hr. Subsequently, total cell lysates were prepared for immunoblot analysis.
(D) GFP-tagged DRAK2 was transfected in HeLa cells. After transfection, cells were treated with or without TGF-b1 for 2 hr and then fixed for immunofluores-
cence. Nuclear translocation of Smad3 was detected using anti-Smad3 antibody.
(E) HeLa cells transiently transfected with Myc-tagged DRAK2 were treated with or without TGF-b1 for 2 hr, and then nuclear proteins were subjected to
immunoblots.
(F) HaCaT cells stably expressing GFP or DRAK2 protein were treated with TGF-b1 for 8 hr, and then total RNAwas isolated. mRNA levels of TGF-b1 target genes
were detected by RT-PCR.
(G) HeLa cells were transfected with HA-tagged TbRI WT or lacking DRAK2-binding site and Myc-tagged DRAK2. After transfection, cells were treated with
TGF-b1 for 1 hr and then subjected to immunoblots.
1290 Cell Reports 2, 1286–1299, November 29, 2012 ª2012 The Authors
Figure 3. Functional Loss of DRAK2 Enhances TGF-b Signaling
(A) DRAK2 kinase activity was measured in 293T cells transfected with empty vector, Myc-tagged DRAK2, or Myc-tagged kinase inactive DRAK2 (K62A). Cell
lysates were incubated in a kinase assay buffer containing 32P-ATP followed by an in vitro kinase assay.
(B) 293T cells were cotransfected with Myc-tagged DRAK2, or Myc-tagged DRAK2 K62A, and HA-tagged TbRI. Cell lysates were immunoprecipitated with
anti-HA antibody and then immunoblotted with indicated antibodies.
(C) Luciferase assays of lysates from HeLa cells were performed using cotransfection of the TGF-b1-responsive reporter CAGA-Luc and control vector,
Myc-tagged DRAK2, or Myc-tagged DRAK2 K62A, after incubation for 16 hr with or without TGF-b1 treatment. Error bars indicate SDM of three independent
experiments.
(D) HeLa cells were cotransfected with control vector, Myc-tagged DRAK2, or Myc-tagged DRAK2 K62A in the presence or the absence of TGF-b1 for 1 hr. Total
cell lysates were prepared for immunoblot analysis.
(E) Lysates of 293T cells cotransfected with Myc-tagged DRAK2 WT, GST-fused DRAK2 WT, Myc-tagged DRAK2 K62A, and/or GST-fused DRAK2 K62A were
subjected to GST pull-down assays and then detected by immunoblots.the tumor compartment of breast carcinomas, possibly repre-
senting two populations of cells (Figure 4E). Notably, strong
nuclear localization of DRAK2 was seen in the epithelial tumor
cell compartment, suggesting an unknown role of DRAK2 in
the nucleus. Next, based on clinical annotations available from
Gene Expression Omnibus (GEO), we analyzed the relapse-
free survival of breast cancer patient cohorts using public
microarray-based breast cancer data sets (Bos et al., 2009).
Patients with high DRAK2 expression were associated with
a significantly shorter relapse-free survival time (p = 0.0063) (Fig-
ure S5). Taken together, these studies revealed that tumor-(H) Luciferase assays of lysates from HeLa cells were performed using cotransfe
HA-tagged TbRI WT or lacking DRAK2-binding site, after incubation for 16 hr wit
experiments.
(I) 293T cells were cotransfected with indicated plasmids and harvested for imm
antibodies.
See also Figures S2, S3, and S4.
Cell Reassociated DRAK2 was predominantly produced by malignant
breast cancer cells.
DRAK2 Knockdown Enhances TGF-b Signaling in Breast
Cancer Cells
Since Hs578T and MDA-MB-231 breast cancer cells exhibited
the highest expression of DRAK2 among the breast cancer cell
lines tested, we hypothesized that DRAK2 may inhibit the
TGF-b signal through interaction with TbRI in vivo in these breast
cancer cell lines. To examine an interaction of DRAK2 with TbRI,
immunoprecipitation experiments were performed. Wection of the TGF-b1-responsive reporter CAGA-Luc, Myc-tagged DRAK2, and
h or without TGF-b1 treatment. Error bars indicate SDM of three independent
unoprecipitation. Bound proteins were identified with anti-HA and anti-Flag
ports 2, 1286–1299, November 29, 2012 ª2012 The Authors 1291
Figure 4. DRAK2 Expression Is Elevated in Primary Breast Cancers
(A) Quantitative RT-PCR of DRAK2 gene expression in various breast cancer cell lines.
(B) Heatmap of a published microarray data set showing the expression levels of ERBB2, ESR1, and DRAK2 across the five breast cancer subtypes.
(C) Comparison of DRAK2 expression in breast cancer subtypes using published microarray data sets.
(D) Expression level of DRAK2 mRNA was performed in six normal tissues and seven triple-negative breast tumor tissues using semiquantitative RT-PCR. 18S
rRNA was used as an internal control.
(E) Histological analysis of normal tissue (top row) and tumor (bottom row) from two breast cancer patients. Left panels, staining with anti-DRAK2-specific
antibody; middle panel, hematoxylin and eosin staining; right panel, staining with antinormal IgG antibody. Original magnification, 3200.
See also Figure S5.observed the endogenous interaction between TbRI and DRAK2
even in the absence of TGF-b1, but TGF-b1 treatment increased
the amount of DRAK2 associated with TbRI (Figure 5A). Interest-
ingly, DRAK2 protein expression was enhanced upon TGF-b1
stimulation. The interaction of TbRI with DRAK2 also was con-
firmed in the in situ PLA. The number of DRAK2/TbRI complexes
per cell was found to be significantly higher in the TGF-b1-
treated cells (visualized as red dots in Figure 5B), suggesting
that TGF-b1 enhances the association between DRAK2 and
TbRI. To examine the role of DRAK2 in TGF-b1-induced tran-1292 Cell Reports 2, 1286–1299, November 29, 2012 ª2012 The Autscription in Hs578T and MDA-MB-231 breast cancer cell lines,
we examined the impact of DRAK2 expression on transcriptional
activation of a TGF-b1-responsive reporter in these cell lines. As
expected, ectopic expression of DRAK2 greatly decreased TGF-
b1-induced transcriptional activity (Figures 5C and 5D). To deter-
mine if loss of DRAK2 expression enhances TGF-b signaling, we
made Hs578T, MDA-MB-231, and HaCaT cell lines stably ex-
pressing DRAK2-specific small hairpin RNA (shRNA) using a
lentiviral system. Inhibition of DRAK2 expression markedly en-
hanced TGF-b1-induced Smad2/3 phosphorylation in Hs578Thors
Figure 5. Knockdown of DRAK2 Increases TGF-b Signaling in Breast Cancer Cell Lines
(A) Hs578T andMDA-MB-231 breast cancer cell lines were treated with or without TGF-b1 for 4 hr, and cell lysates were immunoprecipitated with the antinormal
IgG or anti-TbRI antibodies and then subjected to immunoblots with anti-DRAK2 antibody.
(B) Hs578T and MDA-MB-231 cells treated with TGF-b1 for 4 hr were fixed and assayed with in situ PLA. In situ PLA signals were visualized in red.
(C andD) Luciferase assays using lysates of Hs578T andMDA-MB-231 cells were performed by cotransfection of the TGF-b1-responsive reporter CAGA-Luc and
Myc-tagged DRAK2, after incubation for 16 hr with or without TGF-b1 treatment. Error bars indicate SDM of three independent experiments.
(E) Immunoblot analysis of Hs578T cells stably expressing DRAK2-specific shRNA after TGF-b1 treatment for indicated times.
(F) Immunoblot analysis of MDA-MB-231 cells stably expressing DRAK2-specific shRNA after TGF-b1 treatment for 1 hr.
(G and H) Effect of DRAK2 knockdown on CAGA-Luc reporter activity to TGF-b1 in Hs578T and MDA-MB-231 cells stably expressing DRAK2-specific shRNA;
TGF-b1 was added for 16 hr. Error bars indicate SDM of three independent experiments.
(I) Hs578T and MDA-MB-231 cells stably expressing DRAK2-specific shRNA were treated with TGF-b1 for 8 hr, and then total RNA was isolated. mRNA levels of
TGF-b1 target genes, including p15, p21, PAI1, TMEPAI, Il11, DRAK2, and 18S, were detected by RT-PCR.
(J) Splenocytes isolated from wild-type or drak2-knockout mice were stimulated by anti-CD3 and anti-CD28 antibodies for 2 hr. After TGF-b1 treatment for 1 hr,
cells were collected and lysates were subjected to immunoblot analysis with indicated antibodies.
See also Figure S5.andMDA-MB-231 breast cancer cells (Figures 5E and 5F) aswell
as HaCaT cells (Figure S6A). Next, we sought to examine
whether inhibition of DRAK2 expression further enhances
TGF-b1-induced transcriptional activity. Knockdown of DRAK2Cell Resignificantly increased TGF-b1-induced transcriptional activities
compared to the control (Figures 5G, 5H, and S6B). We also
examined whether depletion of endogenous DRAK2 increases
the expression of direct target genes of TGF-b signaling inports 2, 1286–1299, November 29, 2012 ª2012 The Authors 1293
breast cancer cell lines. In comparison with the control cells,
knockdown of DRAK2 increased the transcriptional level of the
target genes in response to TGF-b1 in both cell lines (Figure 5I).
To further confirm whether DRAK2 physiologically serves
to inhibit TGF-b signaling in vivo, we investigated TGF-b1
responses in splenocytes isolated from drak2 wild-type and
drak2-deficient mice. Splenocytes from drak2-deficient mice
showed much stronger induction of Smad2/3 phosphorylation
by TGF-b1 treatment than splenocytes of drak2 wild-type
mice, consistent with previous results using shRNA-mediated
knockdown (Figure 5J). We also found that Smad2/3 phosphor-
ylation was reproducibly enhanced, even in the inactivated/
unstimulated naive splenocytes of drak2-deficient mice.
TGF-b1 Regulates the Transcriptional Activation
of DRAK2 Promoter
It is known that TGF-b signaling is subject to negative
feedback through TGF-b1-induced transcripts such as Smad7
and TMEPAI. In the results shown above (Figures 2F, 5A,
and 5I), we observed induction of expression of DRAK2 mRNA
or protein by TGF-b1. Thus, we tested whether DRAK2 is a
bona fide TGF-b1-responsive gene. DRAK2 expression was
potently induced by TGF-b1 in many different cell lines: HeLa,
HaCaT, Hs578T, and MDA-MB-231 cells (Figures 6A and S7A).
We then examined whether TbRI kinase activity is required for
the induction of DRAK2 expression by TGF-b1. TGF-b1 treat-
ment induced expression of DRAK2 mRNA, whereas pre-
treatment of cells with a TbRI kinase inhibitor, SB431542,
inhibited TGF-b1-induced DRAK2 mRNA expression (Figures
6B and S7B). In order to investigate whether TGF-b1-induced
DRAK2 expression required de novo protein synthesis, cells
were pretreated with cycloheximide (CHX), a protein synthesis
inhibitor. Expression of DRAK2 mRNA induced by TGF-b1 was
increased in the presence of CHX, suggesting that DRAK2 was
a direct target gene of TGF-b signaling (Figures 6C and S7C).
Thus, DRAK2 is an early TGF-b1-responsive gene that acts in
a negative feedback loop to suppress TGF-b signaling.
To determine whether expression of DRAK2 induced by
TGF-b1 is associated with direct transcriptional activation
of the DRAK2 promoter, a DNA fragment corresponding to
the1 to4,775 bp region of the DRAK2 promoter was inserted
into the upstream of a pGL3 luciferase reporter gene. This pro-
moter fragment contained four putative Smad3-binding sites.
When the DRAK2 promoter reporter construct was cotrans-
fected with constitutively active TbRI (HA-Alk5 ca) into Hs578T
cells, its promoter activity was increased by active TbRI in
a dose-dependent manner (Figure 6D). TGF-b1 treatment also
induced DRAK2 promoter activity, whereas its activity was
blocked by treatment of TbRI kinase inhibitor (Figure 6E). To
further characterize which Smad3-binding site is responsible
for induction of DRAK2 expression by TGF-b1, four DRAK2
promoter deletion constructs were generated by deleting
each putative Smad3-binding site. Deletions up to position
3,510 bp still maintained the responsiveness of DRAK2
promoter to constitutively active TbRI kinase, whereas deletion
of position 3,100 to 3,510 bp abolished the transcriptional
activity of DRAK2 promoter (Figure 6F). Thus, these findings
support the existence of a functional TGF-b1-responsive1294 Cell Reports 2, 1286–1299, November 29, 2012 ª2012 The Autelement within the 3,510 to 4,755 bp region of the DRAK2
promoter. To examine whether TGF-b1 treatment triggers
Smad3 binding to the DRAK2 gene chromatin, we performed
chromatin immunoprecipitation (ChIP) using anti-Smad2/3 anti-
bodies. The 3,035 to 3,359 bp promoter region interacted
with Smad3 independent of TGF-b1 treatment, whereas
TGF-b1 treatment significantly increased the interaction of
Smad3 with the 4,481 to 4,833 bp promoter region. On the
other hand, 2,404 to 2,752 and 4,111 to 4,488 bp regions
did not interact with Smad3 (Figures 6G and S7D). To identify
whether Smad3-binding sites located in 4,481 to 4,833
and 3,035 to 3,359 bp regions are important for TGF-b1-
induced DRAK2 transcription, we generated mutant constructs
for 4,481 to 4,833 and 3,035 to 3,359 bp regions (CAGA
sequence replaced by GAAA). Luciferase activity driven by the
full-length DRAK2 promoter was increased by constitutively
active TbRI kinase; mutation of both putative Smad3-binding
sites in 4,481 to 4,833 and 3,035 to 3,359 bp regions
completely abolished the inducibility of DRAK2 promoter activity
by constitutively active TbRI kinase (Figure 6H). Next, to further
examine whether transcriptional activation of DRAK2 promoter
by TGF-b1 is dependent on Smad3, we used a Smad3-deficient
SNU484 gastric cancer cell to study Smad3 dependency on
TGF-b1-induced DRAK2 promoter activity (Han et al., 2004).
SNU484 cells lacking Smad3 did not respond to TGF-b1-
dependent transcriptional activation of DRAK2 promoter,
whereas ectopic expression of Smad3 rescued the DRAK2
promoter activity upon TGF-b1 treatment (Figure 6I). To exclude
the possibility that the DRAK2 promoter is also regulated by
Smad2, we performed the DRAK2 promoter assay using
Smad2- or Smad3-deficient mouse immortalized mammary
epithelial cells (IMECs) to see whether Smad2 activates DRAK2
promoter activity (Kohn et al., 2010). TGF-b1 induced DRAK2
promoter activity in wild-type IMECs as well as Smad2-deficient
IMECs. However, TGF-b1 did not induce DRAK2 promoter
activity in Smad3-deficient IMECs (Figure S7E). This result
indicates that transcriptional activation of DRAK2 promoter by
TGF-b1 is dependent on Smad3 rather than Smad2. Taken
together, our results indicate that Smad3-binding elements in
the DRAK2 promoter are responsible for transcriptional activa-
tion of DRAK2 by TGF-b1.
Knockdown of DRAK2 Significantly Suppresses Tumor
Growth through Induction of TGF-b1-Mediated Tumor
Suppressor Genes
TGF-b1-mediated cell growth inhibition occurs through induc-
tion of cell-cycle-arrest-related genes, such as p15Ink4b and
p21Waf1/Cip1. As shown in Figure 5I, knockdown of endogenous
DRAK2 enhanced TGF-b1-induced expression of p15INK4b and
p21Waf1/Cip1 genes in Hs578T and MDA-MB-231 cells. Consis-
tent with this observation, depletion of endogenous DRAK2
was antiproliferative in two breast cancer cell lines (Figures 7A
and 7B). To examine whether knockdown of DRAK2 suppresses
the transforming potential, Hs578T and MDA-MB-231 cells that
stably express DRAK2-specific shRNA were seeded in soft agar
plates. Knockdown of DRAK2 resulted in the decrease of
anchorage-independent growth in soft agar compared to the
control cells (Figures 7C and 7D). To confirm whether the losshors
Figure 6. TGF-b1 Regulates the Transcriptional Status of the DRAK2 Promoter
(A) Hs578T and MDA-MB-231 cells were treated with TGF-b1 for indicated times and then RT-PCR (top) and immunoblots (bottom) were performed using
a human DRAK2 primer and anti-DRAK2 antibody.
(B and C) Cells were stimulated with TGF-b1 for 4 hr after pretreatment with SB431542 (TbRI inhibitor) or cycloheximide for 2 hr. Total RNA was isolated and
RT-PCR was carried out.
(D) Hs578T cells were transiently cotransfected with HA-tagged Alk5 ca, and pGL3 control or DRAK2 promoter including from 1 to 4,775 bp. Luciferase
activities were normalized with b-galactosidase. Error bars indicate SDM of three independent experiments.
(E) Hs578T cells transfected with pGL3 control or DRAK2 full promoter were treated with or without TGF-b1 for 16 hr after pretreatment with SB431542 for 2 hr.
(F) Illustration of luciferase reporters including Smad3/4-binding site candidate regions in the DRAK2 promoter sequence (left). Hs578T cells were transfected
with various promoter constructs and HA-tagged Alk5 ca and then treated with or without TGF-b1 for 16 hr. After TGF-b1 treatment, cells were assayed for
luciferase activity. Error bars indicate SDM of three independent experiments.
(G) ChIP analysis showing the recruitment of Smad3 onto humanDRAK2 promoter in the Hs578T cells treatedwith antinormal IgG or anti-DRAK2 antibodies in the
presence or absence of TGF-b1 treatment for 8 hr.
(H) The consensus Smad3-binding sites are underlined and their mutations are shown in lowercase characters (left). Hs578T cells were cotransfected with the
HA-tagged Alk5 ca and pGL3 control, DRAK2 full promoter, or double-mutant reporter containing mutated region II and region IV (CAGA sequence replaced by
GAAA) Smad3 sites and then subjected to luciferase assays. Error bars indicate SDM of three independent experiments.
(I) Smad3-deficient SNU484 gastric cancer cells were cotransfected with Flag-tagged Smad3 and pGL2 control or DRAK2 full promoter sequence reporter and
then treated with or without TGF-b1 for 16 hr. Cell lysates were collected for luciferase assays. Error bars indicate SDM of three independent experiments.
See also Figure S7.
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Figure 7. Knockdown of DRAK2 Significantly Inhibits Tumor Growth through Induction of TGF-b1-Mediated Tumor Suppressor Genes
(A and B) Cell doublings of Hs578T and MDA-MB-231 stably expressing DRAK2-specific shRNA. Each data point represents the mean of cells counted in
triplicate dishes.
(C) Anchorage-independent growth of Hs578T and MDA-MB-231 stably expressing DRAK2-specific shRNA. Photographs of colony formation are shown as
microscopic colonies formed at 3 weeks after seeding.
(D) The number of crystal violet-stained colonies presented is the mean of colony counts in350 microscopic fields from three dishes. Error bars indicate SDM of
three independent experiments.
(E and F) Tumor formation and volumes of Hs578T and MDA-MB-231 cells stably expressing DRAK2-specific shRNA subcutaneously injected into SCID mice.
Error bars indicate SDM of three independent experiments.
(G) Scatter plot comparing global gene expression profiles between the DRAK2 shRNA and control shRNA Hs578T cell lines. Red and green lines indicate 2-fold
differences in either direction of gene expression levels. Boxplot comparing validated gene expression profiles between theDRAK2 shRNA and control shRNA in
Hs578T cell lines was also shown.
(H) RT-PCR validation of genes upregulated in the Hs578T cells stably expressing DRAK2-specific shRNA. Hs578T cells stably expressing control or DRAK2-
specific shRNA were treated with or without TGF-b1 for 16 hr and then subjected to RT-PCR.of DRAK2 expression impacted the tumorigenic capacity in
breast cancer cells in vivo, we tested the tumorigenicity of
Hs578T and MDA-MB-231 cells that stably express either
DRAK2-specific shRNA or control shRNA in immunodeficient
mice. Knockdown of DRAK2 decreased the ability of Hs578T
and MDA-MB-231 cells to form tumors, suggesting that
DRAK2 was required to reinforce tumorigenicity in vivo (Figures1296 Cell Reports 2, 1286–1299, November 29, 2012 ª2012 The Aut7E and 7F). To confirm that reduced tumorigenic potential
causes the induction of tumor suppressor genes, we performed
microarray analyses in Hs578T cells that stably express DRAK2-
specific shRNA. Microarray analysis revealed that knockdown of
DRAK2 induced changes in the gene expression profile. Among
the differentially expressed genes that might be involved in
tumor suppression, ABI3BP (ABI gene family member 3-bindinghors
protein), PANX2 (pannexin2), and SERPINB2 (PAI-2) were
strongly upregulated in cells bearing DRAK2-specific shRNA
(Figure 7G). Next, the expression of these genes was validated
by RT-PCR. Knockdown of DRAK2 increased basal expression
of these genes and expression of PANX2 and ABI3BP genes
was strongly induced by TGF-b1 (Figure 7H). Taken together,
these results suggest that DRAK2 may promote tumorigenesis
by downregulating expression of tumor suppressor genes, in
part, through suppression of TGF-b1 tumor suppressor activity.
DISCUSSION
It is well known that the TGF-b signal transduction pathway is
tightly controlled by various positive and negative regulatory
nodes. Each step in the TGF-b signaling pathway is under
intense regulation to maintain a balance between positive and
negative control. Dysregulation of this pathway can lead to
various diseases, including inflammatory diseases as well as
cancer development (Massague´ et al., 2000; Massague´, 2008).
Our results here indicate that DRAK2 serves as a TGF-b1-
inducible molecule that plays a role in terminating TGF-b
signaling. DRAK2 directly binds to TbRI and this interaction
prevents Smad2 and Smad3 from active participation in TGF-b
signaling. Because TGF-b1 rapidly induces expression of
DRAK2 mRNA, it is likely that DRAK2 may participate in a nega-
tive feedback loop to control TGF-b1 responses and control the
intensity and duration of TGF-b signaling. Our findings provide
evidence for a unique role of DRAK2 as a negative regulator of
TGF-b signaling that shows immediately early response in the
TGF-b signaling pathway.
Several proteins, including Smad7 and TMEPAI, which are
themselves TGF-b1 target genes, have been reported to play
negative roles in the regulation of TGF-b signaling by either pre-
venting interaction of R-Smads with TbRI or inhibiting activation
of R-Smads. Previous studies have shown that Smad7 associ-
ates stably with the activated TbRI to inhibit TGF-b signaling by
preventing access of Smad2/3 to the receptor kinase domain
(Hayashi et al., 1997). Smad7 also recruits the HECT type of E3
ubiquitin ligases, Smurf1/2, and leads to the degradation of
TbRI through the proteasomal pathway (Kavsak et al., 2000;
Ebisawa et al., 2001). TMEPAI is known to antagonize TGF-b1-
induced R-Smads phosphorylation by competing with SARA
for binding to R-Smads (Watanabe et al., 2010). Unlike Smad7
or TMEPAI, DRAK2 does not induce the degradation of TbRI or
compete with SARA for the interaction with receptors. Instead,
DRAK2 represents a naturally occurring receptor kinase antago-
nist that functions to inhibit TGF-b signaling through direct
physical interaction with TbRI, thereby blocking the interaction
between activated TbRI and R-Smads. Interestingly, DRAK2
interacts with TbRI regardless of the activation status of TbRI,
while Smad7 only interacts with the activated TbRI. This finding
suggests that DRAK2may be a general inhibitor that functions at
a very early step in the TGF-b signaling pathway. To support this,
we confirmed that overexpression of DRAK2 suppressed TGF-
b1-induced TMEPAI expression, whereas depletion of DRAK2
by specific shRNA significantly enhanced its expression. Thus,
it is likely that DRAK2 constitutively restricts TbRI kinase activity
to block its downstream signaling. These conclusions are con-Cell Resistent with the general suppression that we observed in all of
the transcriptional reporter assays, and in target gene ex-
pression assays in cells either overexpressing DRAK2 or reduc-
ing DRAK2 expression by specific shRNA employed to study
TGF-b signaling.
DRAK2 kinase activity is regulated in a calcium-dependent
manner. DRAK2 is phosphorylated on at least two distinct sites,
Ser10 and Ser12. The Ser12 site for autophosphorylation has been
shown to play key roles inmodulating the function of DRAK2. The
earlier study demonstrated that Ser12 phosphorylation is neces-
sary for optimal suppression of T cell activation by this kinase
(Friedrich et al., 2007). However, Ser12 mutation did not interfere
with kinase activity. We also found that the S12Amutant retained
the inhibitory activity of TGF-b signaling (data not shown). Most
surprisingly, the kinase-inactive mutant of DRAK2 was almost
completely inactive in suppressing TGF-b signaling, and its
binding activity to TbRI was markedly reduced (Figure 3). Based
onwork presented here, we have shown that proper dimerization
is critical in enhancing the binding affinity to TbRI leading to
the suppression of TGF-b signaling. In this case, the proper
homodimerization of DRAK2 can occur only when each DRAK2
monomer is catalytically active. This suggests that monomer
autophosphorylation may be required for homodimerization.
DRAK2 dimerization may affect the binding to TbRI by imposing,
for example, via a conformational change in the structure of
DRAK2, thereby facilitating interactions with TbRI. Further anal-
ysis of DRAK2 phosphorylation and dimerization events, com-
bined with molecular modeling of the catalytic domain, will
establish the novel mode of action of this kinase.
We demonstrated that the transcriptional regulation of DRAK2
by TGF-b1 is mediated through a rapid and direct Smad3-
dependent signaling mechanism. TGF-b1 treatment rapidly in-
duces DRAK2 expression, resulting in increased interactions
between endogenous TbRI and DRAK2. This interaction was
found to occur in the cytoplasm and near the plasmamembrane.
The ability of the DRAK2 promoter to respond to TGF-b1 is there-
fore believed to play a central role in the negative autoregulation
of TGF-b signaling. However, they do not rule out the possibility
that this protein kinase may fulfill other functions in normal phys-
iology. In addition to suppressing TGF-b signaling within the
cytosol, DRAK2 is predominantly localized in the nucleus in the
breast cancer cells analyzed, even in the presence of TGF-b1.
Although this has not yet been directly investigated, a possible
nuclear role for DRAK2 may be in the regulation of transcrip-
tion. This observation is supported by the microarray analysis
of genes regulated by DRAK2. Furthermore, DRAK2 is known
to be induced by combinatory network of proinflammatory cyto-
kines, such as IFN-g with IL-1b or TNF-a with IL-1b (Mao et al.,
2009). Thus, DRAK2 not only is a TGF-b1-induced antagonist
but is also involved in fine-tuning the cellular response to
TGF-b1, by integrating different signaling pathways.
All members of the DAPK family have been shown to induce
apoptosis upon ectopic expression in various cell types (Ko¨qel
et al., 2001). However, the role of DRAK2 in apoptosis has
been controversial. Its ability to induce apoptosis seems to
depend on the level of expression, the cell types studied, and
the intracellular localization of the kinase. Upregulation of
DRAK2 by inflammatory stimuli results in increased apoptosisports 2, 1286–1299, November 29, 2012 ª2012 The Authors 1297
of islet b cells and T cells (Mao et al., 2006, 2009). In contrast,
other studies have reported that drak2-deficient mice did not
show any defects in T cell apoptosis, suggesting that DRAK2
may function in maintaining the survival of proliferating T cells
(McGargill et al., 2004; Ramos et al., 2008). Moreover, analysis
of potential tumor-associated genes expressed in cutaneous
T cell lymphoma (CTCL) revealed enhanced DRAK2 expression
in the sera or tumor tissues of CTCL patients, but not in healthy
donors (Hartmann et al., 2008).
In numerous tumors, the disruption of TGF-b signaling has
shown to be a critical step in the development of tumorigenic
potential. The underlying mechanism of resistance to the growth
inhibitory effect of TGF-b1 in malignant cells involves the altered
expression as well as inactivating mutations of either receptors
or components of the signaling pathways such as Smad3 or
Smad4. The fact that the DRAK2 protein functions as an antag-
onist of TGF-b signaling suggests that amplified expression of
this protein in human breast cancers might promote suppression
of TGF-b signals in tumors. Indeed, our studies demonstrated
that the elevation of DRAK2 expression contributes to the
progression of human breast cancer. Depletion of DRAK2
markedly decreased the proliferation of breast cancer cell lines
and suppressed tumorigenic capacity. Further supporting this
hypothesis, overexpression of DRAK2 is observed in basal-like
and HER2-enriched breast tumors compared to normal and
luminal cell types. Future studies will provide a deeper insight
into the role of this pathway during tumorigenesis.
In conclusion, we have demonstrated that DRAK2 is a negative
regulator of TGF-b signaling, inhibiting the phosphorylation of
R-Smads through its interaction with TbRI. Our findings
presented here implicate a function of DRAK2 in the limiting of
TGF-b1 growth inhibitory activity. Considering the evidence
that aberrant expression of components related to TGF-b
signaling is strongly linked to tumorigenicity in breast cancer,




Cell cultures, reagents, antibodies, and transfections are described in detail in
the Extended Experimental Procedures.
Lentiviral shRNAs for DRAK2
DRAK2 shRNA (TRC781) lentiviral vectors (Sigma-Aldrich) were used for
knockdown of DRAK2.
Immunoprecipitation and Immunoblot Analysis
Trasnfected or untransfected cells were washed twice in cold PBS and lysed in
IP buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 2 mM EDTA, 10% glycerol) plus phosphatase and protease
inhibitors (Roche). Whole-cell extracts were incubated with the appropriate
primary antibodies overnight at 4C. Antibody-bound proteins were precipi-
tated with protein A/G beads according to the protocol provided by the manu-
facturer. After the beads were washed three times with lysis buffer, they were
eluted in 2 3 SDS sample loading buffer. Eluted proteins were separated by
SDS-PAGE and then detected by immunoblots.
In Situ Proximity Ligation Assay
In situ PLA was performed according to the manufacturer’s protocol (Olink
Bioscience). Cells were immediately fixed in 4% paraformaldehyde in 4C1298 Cell Reports 2, 1286–1299, November 29, 2012 ª2012 The Autfor 30 min. Slides were blocked, incubated with antibodies directed against
Myc, HA, TbRI, and DRAK2 and then incubated with PLA PLUS and MINUS
probe for anti-mouse and anti-rabbit, which secondary antibodies conjugated
to unique oligonucleotides. Slides were mounted with Vectashield mounting
media (Vector Laboratories), and immunofluorescence images were obtained
by the confocal microscope.
Chromatin Immunoprecipitation
ChIPs were carried out according to the Millipore protocol. The detail proce-
dures were described in the Extended Experimental Procedures.
Tumorigenicity
Hs578T and MDA-MB-231 breast cancer cell lines stably expressing
control vector or DRAK2-specific shRNA (5 3 106) were injected subcutane-
ously into the flanks of SCID mice. Tumor dimensions were measured
twice weekly. Mice were sacrificed at 9 weeks after injection, and tumors
were surgically isolated. Tumor volume (V) was calculated by using the for-
mula (S 3 S 3 L) 3 0.5, where S and L were the short and long dimen-
sions, respectively. All animals weremaintained according to the CHAHospital
Animal Care and Use Committee guidelines under protocol number
IACUC110004.
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